Global RNA-Targeted Small Molecules Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.

Published Aug 16, 2025

Length 194 Pages

SKU # APRC20360430

Description

Summary

According to APO Research, the global RNA-Targeted Small Molecules market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for RNA-Targeted Small Molecules is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for RNA-Targeted Small Molecules is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the RNA-Targeted Small Molecules market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for RNA-Targeted Small Molecules is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the RNA-Targeted Small Molecules market include Twentyeight-Seven Therapeutics, STORM Therapeutics, Skyhawk Therapeutics, Ribometrix, H3 Biomedicine, Gotham Therapeutics, Expansion Therapeutics, Epics Therapeutics and Arrakis Pharmaceuticals, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for RNA-Targeted Small Molecules, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of RNA-Targeted Small Molecules, also provides the value of main regions and countries. Of the upcoming market potential for RNA-Targeted Small Molecules, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the RNA-Targeted Small Molecules revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global RNA-Targeted Small Molecules market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global RNA-Targeted Small Molecules company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
RNA-Targeted Small Molecules Segment by Company

Twentyeight-Seven Therapeutics
STORM Therapeutics
Skyhawk Therapeutics
Ribometrix
H3 Biomedicine
Gotham Therapeutics
Expansion Therapeutics
Epics Therapeutics
Arrakis Pharmaceuticals
Anima Biotech Inc.
Accent Therapeutics
RNA-Targeted Small Molecules Segment by Type

mRNA Translation Regulation
RNA Splicing Modification
Indirect RNA Targeting - Epitranscriptomics
Direct RNA Targeting
RNA-Targeted Small Molecules Segment by Application

Laboratories
Hospitals
Phamacy
RNA-Targeted Small Molecules Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global RNA-Targeted Small Molecules status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the RNA-Targeted Small Molecules key companies, revenue, market share, and recent developments.
3. To split the RNA-Targeted Small Molecules breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions RNA-Targeted Small Molecules market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify RNA-Targeted Small Molecules significant trends, drivers, influence factors in global and regions.
6. To analyze RNA-Targeted Small Molecules competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA-Targeted Small Molecules market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of RNA-Targeted Small Molecules and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA-Targeted Small Molecules.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global RNA-Targeted Small Molecules industry.
Chapter 3: Detailed analysis of RNA-Targeted Small Molecules company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of RNA-Targeted Small Molecules in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of RNA-Targeted Small Molecules in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

1 Market Overview: 1.1 Product Definition; 1.2 Global RNA-Targeted Small Molecules Market Size, 2020 VS 2024 VS 2031; 1.3 Global RNA-Targeted Small Molecules Market Size (2020-2031); 1.4 Assumptions and Limitations; 1.5 Study Goals and Objectives
2 RNA-Targeted Small Molecules Market Dynamics: 2.1 RNA-Targeted Small Molecules Industry Trends; 2.2 RNA-Targeted Small Molecules Industry Drivers; 2.3 RNA-Targeted Small Molecules Industry Opportunities and Challenges; 2.4 RNA-Targeted Small Molecules Industry Restraints
3 RNA-Targeted Small Molecules Market by Company: 3.1 Global RNA-Targeted Small Molecules Company Revenue Ranking in 2024; 3.2 Global RNA-Targeted Small Molecules Revenue by Company (2020-2025); 3.3 Global RNA-Targeted Small Molecules Company Ranking (2023-2025); 3.4 Global RNA-Targeted Small Molecules Company Manufacturing Base and Headquarters; 3.5 Global RNA-Targeted Small Molecules Company Product Type and Application; 3.6 Global RNA-Targeted Small Molecules Company Establishment Date; 3.7 Market Competitive Analysis; 3.7.1 Global RNA-Targeted Small Molecules Market Concentration Ratio (CR5 and HHI); 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024; 3.7.3 2024 RNA-Targeted Small Molecules Tier 1, Tier 2, and Tier 3 Companies; 3.8 Mergers and Acquisitions Expansion
4 RNA-Targeted Small Molecules Market by Type: 4.1 RNA-Targeted Small Molecules Type Introduction; 4.1.1 mRNA Translation Regulation; 4.1.2 RNA Splicing Modification; 4.1.3 Indirect RNA Targeting - Epitranscriptomics; 4.1.4 Direct RNA Targeting; 4.2 Global RNA-Targeted Small Molecules Sales Value by Type; 4.2.1 Global RNA-Targeted Small Molecules Sales Value by Type (2020 VS 2024 VS 2031); 4.2.2 Global RNA-Targeted Small Molecules Sales Value by Type (2020-2031); 4.2.3 Global RNA-Targeted Small Molecules Sales Value Share by Type (2020-2031)
5 RNA-Targeted Small Molecules Market by Application: 5.1 RNA-Targeted Small Molecules Application Introduction; 5.1.1 Laboratories; 5.1.2 Hospitals; 5.1.3 Phamacy; 5.2 Global RNA-Targeted Small Molecules Sales Value by Application; 5.2.1 Global RNA-Targeted Small Molecules Sales Value by Application (2020 VS 2024 VS 2031); 5.2.2 Global RNA-Targeted Small Molecules Sales Value by Application (2020-2031); 5.2.3 Global RNA-Targeted Small Molecules Sales Value Share by Application (2020-2031)
6 RNA-Targeted Small Molecules Regional Value Analysis: 6.1 Global RNA-Targeted Small Molecules Sales Value by Region: 2020 VS 2024 VS 2031; 6.2 Global RNA-Targeted Small Molecules Sales Value by Region (2020-2031); 6.2.1 Global RNA-Targeted Small Molecules Sales Value by Region: 2020-2025; 6.2.2 Global RNA-Targeted Small Molecules Sales Value by Region (2026-2031); 6.3 North America; 6.3.1 North America RNA-Targeted Small Molecules Sales Value (2020-2031); 6.3.2 North America RNA-Targeted Small Molecules Sales Value Share by Country, 2024 VS 2031; 6.4 Europe; 6.4.1 Europe RNA-Targeted Small Molecules Sales Value (2020-2031); 6.4.2 Europe RNA-Targeted Small Molecules Sales Value Share by Country, 2024 VS 2031; 6.5 Asia-Pacific; 6.5.1 Asia-Pacific RNA-Targeted Small Molecules Sales Value (2020-2031); 6.5.2 Asia-Pacific RNA-Targeted Small Molecules Sales Value Share by Country, 2024 VS 2031; 6.6 South America; 6.6.1 South America RNA-Targeted Small Molecules Sales Value (2020-2031); 6.6.2 South America RNA-Targeted Small Molecules Sales Value Share by Country, 2024 VS 2031; 6.7 Middle East & Africa; 6.7.1 Middle East & Africa RNA-Targeted Small Molecules Sales Value (2020-2031); 6.7.2 Middle East & Africa RNA-Targeted Small Molecules Sales Value Share by Country, 2024 VS 2031
7 RNA-Targeted Small Molecules Country-level Value Analysis: 7.1 Global RNA-Targeted Small Molecules Sales Value by Country: 2020 VS 2024 VS 2031; 7.2 Global RNA-Targeted Small Molecules Sales Value by Country (2020-2031); 7.2.1 Global RNA-Targeted Small Molecules Sales Value by Country (2020-2025); 7.2.2 Global RNA-Targeted Small Molecules Sales Value by Country (2026-2031); 7.3 USA; 7.3.1 USA RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.3.2 USA RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.3.3 USA RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.4 Canada; 7.4.1 Canada RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.4.2 Canada RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.4.3 Canada RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.5 Mexico; 7.5.1 Mexico RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.5.2 Mexico RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.5.3 Mexico RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.6 Germany; 7.6.1 Germany RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.6.2 Germany RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.6.3 Germany RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.7 France; 7.7.1 France RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.7.2 France RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.7.3 France RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.8 U.K.; 7.8.1 U.K. RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.8.2 U.K. RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.8.3 U.K. RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.9 Italy; 7.9.1 Italy RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.9.2 Italy RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.9.3 Italy RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.10 Spain; 7.10.1 Spain RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.10.2 Spain RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.10.3 Spain RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.11 Russia; 7.11.1 Russia RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.11.2 Russia RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.11.3 Russia RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.12 Netherlands; 7.12.1 Netherlands RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.12.2 Netherlands RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.12.3 Netherlands RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.13 Nordic Countries; 7.13.1 Nordic Countries RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.13.2 Nordic Countries RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.13.3 Nordic Countries RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.14 China; 7.14.1 China RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.14.2 China RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.14.3 China RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.15 Japan; 7.15.1 Japan RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.15.2 Japan RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.15.3 Japan RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.16 South Korea; 7.16.1 South Korea RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.16.2 South Korea RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.16.3 South Korea RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.17 India; 7.17.1 India RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.17.2 India RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.17.3 India RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.18 Australia; 7.18.1 Australia RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.18.2 Australia RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.18.3 Australia RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.19 Southeast Asia; 7.19.1 Southeast Asia RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.19.2 Southeast Asia RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.19.3 Southeast Asia RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.20 Brazil; 7.20.1 Brazil RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.20.2 Brazil RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.20.3 Brazil RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.21 Argentina; 7.21.1 Argentina RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.21.2 Argentina RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.21.3 Argentina RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.22 Chile; 7.22.1 Chile RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.22.2 Chile RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.22.3 Chile RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.23 Colombia; 7.23.1 Colombia RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.23.2 Colombia RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.23.3 Colombia RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.24 Peru; 7.24.1 Peru RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.24.2 Peru RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.24.3 Peru RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.25 Saudi Arabia; 7.25.1 Saudi Arabia RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.25.2 Saudi Arabia RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.25.3 Saudi Arabia RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.26 Israel; 7.26.1 Israel RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.26.2 Israel RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.26.3 Israel RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.27 UAE; 7.27.1 UAE RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.27.2 UAE RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.27.3 UAE RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.28 Turkey; 7.28.1 Turkey RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.28.2 Turkey RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.28.3 Turkey RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.29 Iran; 7.29.1 Iran RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.29.2 Iran RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.29.3 Iran RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031; 7.30 Egypt; 7.30.1 Egypt RNA-Targeted Small Molecules Sales Value Growth Rate (2020-2031); 7.30.2 Egypt RNA-Targeted Small Molecules Sales Value Share by Type, 2024 VS 2031; 7.30.3 Egypt RNA-Targeted Small Molecules Sales Value Share by Application, 2024 VS 2031
8 Company Profiles: 8.1 Twentyeight-Seven Therapeutics; 8.1.1 Twentyeight-Seven Therapeutics Comapny Information; 8.1.2 Twentyeight-Seven Therapeutics Business Overview; 8.1.3 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (2020-2025); 8.1.4 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecules Product Portfolio; 8.1.5 Twentyeight-Seven Therapeutics Recent Developments; 8.2 STORM Therapeutics; 8.2.1 STORM Therapeutics Comapny Information; 8.2.2 STORM Therapeutics Business Overview; 8.2.3 STORM Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (2020-2025); 8.2.4 STORM Therapeutics RNA-Targeted Small Molecules Product Portfolio; 8.2.5 STORM Therapeutics Recent Developments; 8.3 Skyhawk Therapeutics; 8.3.1 Skyhawk Therapeutics Comapny Information; 8.3.2 Skyhawk Therapeutics Business Overview; 8.3.3 Skyhawk Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (2020-2025); 8.3.4 Skyhawk Therapeutics RNA-Targeted Small Molecules Product Portfolio; 8.3.5 Skyhawk Therapeutics Recent Developments; 8.4 Ribometrix; 8.4.1 Ribometrix Comapny Information; 8.4.2 Ribometrix Business Overview; 8.4.3 Ribometrix RNA-Targeted Small Molecules Revenue and Gross Margin (2020-2025); 8.4.4 Ribometrix RNA-Targeted Small Molecules Product Portfolio; 8.4.5 Ribometrix Recent Developments; 8.5 H3 Biomedicine; 8.5.1 H3 Biomedicine Comapny Information; 8.5.2 H3 Biomedicine Business Overview; 8.5.3 H3 Biomedicine RNA-Targeted Small Molecules Revenue and Gross Margin (2020-2025); 8.5.4 H3 Biomedicine RNA-Targeted Small Molecules Product Portfolio; 8.5.5 H3 Biomedicine Recent Developments; 8.6 Gotham Therapeutics; 8.6.1 Gotham Therapeutics Comapny Information; 8.6.2 Gotham Therapeutics Business Overview; 8.6.3 Gotham Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (2020-2025); 8.6.4 Gotham Therapeutics RNA-Targeted Small Molecules Product Portfolio; 8.6.5 Gotham Therapeutics Recent Developments; 8.7 Expansion Therapeutics; 8.7.1 Expansion Therapeutics Comapny Information; 8.7.2 Expansion Therapeutics Business Overview; 8.7.3 Expansion Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (2020-2025); 8.7.4 Expansion Therapeutics RNA-Targeted Small Molecules Product Portfolio; 8.7.5 Expansion Therapeutics Recent Developments; 8.8 Epics Therapeutics; 8.8.1 Epics Therapeutics Comapny Information; 8.8.2 Epics Therapeutics Business Overview; 8.8.3 Epics Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (2020-2025); 8.8.4 Epics Therapeutics RNA-Targeted Small Molecules Product Portfolio; 8.8.5 Epics Therapeutics Recent Developments; 8.9 Arrakis Pharmaceuticals; 8.9.1 Arrakis Pharmaceuticals Comapny Information; 8.9.2 Arrakis Pharmaceuticals Business Overview; 8.9.3 Arrakis Pharmaceuticals RNA-Targeted Small Molecules Revenue and Gross Margin (2020-2025); 8.9.4 Arrakis Pharmaceuticals RNA-Targeted Small Molecules Product Portfolio; 8.9.5 Arrakis Pharmaceuticals Recent Developments; 8.10 Anima Biotech Inc.; 8.10.1 Anima Biotech Inc. Comapny Information; 8.10.2 Anima Biotech Inc. Business Overview; 8.10.3 Anima Biotech Inc. RNA-Targeted Small Molecules Revenue and Gross Margin (2020-2025); 8.10.4 Anima Biotech Inc. RNA-Targeted Small Molecules Product Portfolio; 8.10.5 Anima Biotech Inc. Recent Developments; 8.11 Accent Therapeutics; 8.11.1 Accent Therapeutics Comapny Information; 8.11.2 Accent Therapeutics Business Overview; 8.11.3 Accent Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (2020-2025); 8.11.4 Accent Therapeutics RNA-Targeted Small Molecules Product Portfolio; 8.11.5 Accent Therapeutics Recent Developments
9 Concluding Insights
10 Appendix: 10.1 Reasons for Doing This Study; 10.2 Research Methodology; 10.3 Research Process; 10.4 Authors List of This Report; 10.5 Data Source; 10.5.1 Secondary Sources; 10.5.2 Primary Sources

Pricing

Currency Rates

Single User Email from Publisher $4,250
Multi User License Fulfilled by Publisher $6,375
Global Site License Email from Publisher $8,500

How Do Licenses Work?

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now